Biosimilars Litigation: Past, Present and Future

Last year, the FDA approved the first biosimilar drug under the Biologics Price Competition and Innovation Act of 2009 (BPCIA) and the courts have recently rendered some important statutory interpretations. This represents the dawn of a new era in the approval and marketing of biologic products.

Join Fish attorneys Tasha Francisand Michael Amon for our fourth presentation in our webinar series focusing on biologics. This presentation will discuss past, present, and expected litigation in the area, and will focus specifically on the following:

• Recent cases and their impact on the biosimilars industry
• Key interpretation of the BPCIA statute
• Strategies for biologics litigation